BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

394 related articles for article (PubMed ID: 26167500)

  • 1. Immunotherapy for Bone and Soft Tissue Sarcomas.
    Uehara T; Fujiwara T; Takeda K; Kunisada T; Ozaki T; Udono H
    Biomed Res Int; 2015; 2015():820813. PubMed ID: 26167500
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy: A New (and Old) Approach to Treatment of Soft Tissue and Bone Sarcomas.
    Nathenson MJ; Conley AP; Sausville E
    Oncologist; 2018 Jan; 23(1):71-83. PubMed ID: 28935774
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospects and Advances in Adoptive Natural Killer Cell Therapy for Unmet Therapeutic Needs in Pediatric Bone Sarcomas.
    Bareke H; Ibáñez-Navarro A; Guerra-García P; González Pérez C; Rubio-Aparicio P; Plaza López de Sabando D; Sastre-Urgelles A; Ortiz-Cruz EJ; Pérez-Martínez A
    Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37176035
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy for sarcomas.
    Nakata E; Fujiwara T; Kunisada T; Ito T; Takihira S; Ozaki T
    Jpn J Clin Oncol; 2021 Apr; 51(4):523-537. PubMed ID: 33611603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy of sarcomas.
    Leventhal BG
    Natl Cancer Inst Monogr; 1981 Apr; (56):183-7. PubMed ID: 6170891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy of heterogenous sarcomas: questions and strategies.
    Dufresne A; Meurgey A; Brahmi M
    Curr Opin Oncol; 2019 Jul; 31(4):304-309. PubMed ID: 31033565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current status of immunotherapy for sarcomas.
    Miwa S; Nishida H; Tsuchiya H
    Immunotherapy; 2017 Dec; 9(16):1331-1338. PubMed ID: 29185391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase 1/2 study of immunotherapy with dendritic cells pulsed with autologous tumor lysate in patients with refractory bone and soft tissue sarcoma.
    Miwa S; Nishida H; Tanzawa Y; Takeuchi A; Hayashi K; Yamamoto N; Mizukoshi E; Nakamoto Y; Kaneko S; Tsuchiya H
    Cancer; 2017 May; 123(9):1576-1584. PubMed ID: 28241093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy of Childhood Sarcomas.
    Roberts SS; Chou AJ; Cheung NK
    Front Oncol; 2015; 5():181. PubMed ID: 26301204
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy in soft tissue and bone sarcoma: unraveling the barriers to effectiveness.
    Panagi M; Pilavaki P; Constantinidou A; Stylianopoulos T
    Theranostics; 2022; 12(14):6106-6129. PubMed ID: 36168619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of soft tissue and bone sarcomas: review of studies at the National Cancer Institute.
    Rosenberg SA
    Natl Cancer Inst Monogr; 1981 Apr; (56):241-4. PubMed ID: 7029292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancing Natural Killer Cell Targeting of Pediatric Sarcoma.
    Omer N; Nicholls W; Ruegg B; Souza-Fonseca-Guimaraes F; Rossi GR
    Front Immunol; 2021; 12():791206. PubMed ID: 34804076
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biologic therapy for osteosarcoma using liposome-encapsulated muramyl tripeptide.
    Kleinerman ES
    Hematol Oncol Clin North Am; 1995 Aug; 9(4):927-38. PubMed ID: 7490249
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment recommendations for osteosarcoma and adult soft tissue sarcomas.
    Picci P; Ferrari S; Bacci G; Gherlinzoni F
    Drugs; 1994 Jan; 47(1):82-92. PubMed ID: 7510623
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Secondary malignant neoplasms after bone and soft tissue sarcomas in children, adolescents, and young adults.
    Kube SJ; Blattmann C; Bielack SS; Kager L; Kaatsch P; Kühne T; Sorg B; Kevric M; Jabar S; Hallmen E; Sparber-Sauer M; Klingebiel T; Koscielniak E; Dirksen U; Hecker-Nolting S; Gerß JWO
    Cancer; 2022 May; 128(9):1787-1800. PubMed ID: 35195899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic Targets for Bone and Soft-Tissue Sarcomas.
    Miwa S; Yamamoto N; Hayashi K; Takeuchi A; Igarashi K; Tsuchiya H
    Int J Mol Sci; 2019 Jan; 20(1):. PubMed ID: 30621224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PD-1, PD-L1, IDO, CD70 and microsatellite instability as potential targets to prevent immune evasion in sarcomas.
    Siozopoulou V; Smits E; Zwaenepoel K; Liu J; Pouliakis A; Pauwels PA; Marcq E
    Immunotherapy; 2023 Oct; 15(15):1257-1273. PubMed ID: 37661910
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Solid tumors: sarcomas of bone and soft tissue].
    Sommelet D
    Arch Pediatr; 1999; 6 Suppl 2():337s-340s. PubMed ID: 10370528
    [No Abstract]   [Full Text] [Related]  

  • 19. Is amputation necessary for sarcomas? A seven-year experience with limb salvage.
    Eilber FR; Mirra JJ; Grant TT; Weisenburger T; Morton DL
    Ann Surg; 1980; 192(4):431-8. PubMed ID: 6932827
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progress and opportunities for immune therapeutics in osteosarcoma.
    Lettieri CK; Appel N; Labban N; Lussier DM; Blattman JN; Hingorani P
    Immunotherapy; 2016 Oct; 8(10):1233-44. PubMed ID: 27605071
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.